FI971750A - Compositions and treatment for multiple sclerosis - Google Patents

Compositions and treatment for multiple sclerosis Download PDF

Info

Publication number
FI971750A
FI971750A FI971750A FI971750A FI971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A FI 971750 A FI971750 A FI 971750A
Authority
FI
Finland
Prior art keywords
compositions
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
FI971750A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI971750A0 (en
Inventor
Dawn Smilek
Michael Samson
Malcolm Gefter
Di-Hwei Hsu
Jia-Dong Shi
Xavier Paliard
Brigitte Devaux
Jonathan Rothbard
Henry Franzen
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of FI971750A0 publication Critical patent/FI971750A0/en
Publication of FI971750A publication Critical patent/FI971750A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
FI971750A 1994-10-25 1997-04-24 Compositions and treatment for multiple sclerosis FI971750A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (2)

Publication Number Publication Date
FI971750A0 FI971750A0 (en) 1997-04-24
FI971750A true FI971750A (en) 1997-06-24

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971750A FI971750A (en) 1994-10-25 1997-04-24 Compositions and treatment for multiple sclerosis

Country Status (15)

Country Link
EP (1) EP0787147A1 (en)
JP (1) JPH10504039A (en)
AU (1) AU4278296A (en)
BR (1) BR9509438A (en)
CA (1) CA2203629A1 (en)
CZ (1) CZ122697A3 (en)
FI (1) FI971750A (en)
HU (1) HUT77047A (en)
IL (1) IL115766A0 (en)
IS (1) IS4466A (en)
NO (1) NO971900L (en)
PL (1) PL324091A1 (en)
SI (1) SI9520118A (en)
SK (1) SK51297A3 (en)
WO (1) WO1996012737A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
JP4340329B2 (en) 1996-03-21 2009-10-07 サーカッシア リミテッド Latent peptides and methods for identifying them
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (en) * 1997-09-11 1997-09-11 Astra Ab Peptides
WO1999057241A2 (en) * 1998-05-05 1999-11-11 Corixa Corporation Myelin basic protein peptides and uses thereof
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
CA2328612A1 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co., Ltd. Activated t cells, nervous system-specific antigens and their uses
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) 2002-02-01 2002-03-20 Univ Bristol Peptide
MXPA04009361A (en) 2002-03-27 2005-05-17 Aegera Therapeutics Inc Antisense iap nucleobase oligomers and uses thereof.
DE10230381A1 (en) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Use of inhibitors of alanyl aminopeptidases and pharmaceutical compositions comprising them
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
EP2328908A4 (en) * 2008-08-28 2012-11-28 Univ New York State Res Found Treatment of amyloidoses using myelin basic protein and fragments thereof
US20120082644A1 (en) 2009-03-31 2012-04-05 Mannie Mark D Cytokines and neuroantigens for treatment of immune disorders
CN102781465A (en) 2009-10-12 2012-11-14 生命生物实验室有限公司 Composition for treatment of multiple sclerosis
RU2448685C2 (en) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Liposomes containing oligopeptides - fragments of myelin basic protein, pharmaceutical composition and method of treating multiple sclerosis
US8956878B2 (en) 2011-03-21 2015-02-17 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (HSPS) and HSP associated complexes (HACS) and their use in diagnosis and therapy
EP3094379A4 (en) 2014-01-13 2017-06-28 Berg LLC Enolase 1 (eno1) compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE258065T1 (en) * 1987-06-24 2004-02-15 Brigham & Womens Hospital TREATMENT OF AUTOIMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTOANTIGENS
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
AU642693B2 (en) * 1989-12-20 1993-10-28 Autoimmune, Inc. Improved treatment of autoimmune diseases by aerosol administration of auto antigens
CA2077340A1 (en) * 1990-03-02 1991-09-03 Howard L. Weiner Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
WO1993009810A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Mhc subunit conjugates useful in ameliorating deleterious immune responses
ATE228373T1 (en) * 1992-02-28 2002-12-15 Autoimmune Inc SUPPRESSION OF AUTOIMMUNE DISEASES BY ANTIGENS IN WAITING
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
IL105347A0 (en) * 1992-04-09 1993-08-18 Autoimmune Corp Multiple sclerosis t-cell receptor
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
IL106720A (en) * 1992-08-17 1998-10-30 Autoimmune Inc Use of a bystander antigen to prepare compositions for treating retroviral-associated neurological disease in a mammal and such compositions
WO1995006727A2 (en) * 1993-09-03 1995-03-09 Immulogic Pharmaceutical Corporation Uses of myelin oligodendrocyte glycoprotein and peptide portions thereof in protocols related to autoimmune disease
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
AU695801B2 (en) * 1993-09-22 1998-08-20 Board Of Trustees Of The Leland Stanford Junior University Interaction of T-cell receptors and antigen in autoimmune disease
CA2187345A1 (en) * 1994-04-08 1995-10-19 Howard L. Weiner Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
HUT74900A (en) * 1994-04-08 1997-02-28 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or type i interferon
AU2470595A (en) * 1994-05-10 1995-11-29 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
DK0764273T3 (en) * 1994-06-09 1999-06-23 Tno Alpha B crystallin for use in the diagnosis and therapy of autoimmune diseases, especially multiple sclerosis
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
DE69525544T2 (en) * 1994-11-18 2002-08-22 Neurocrine Biosciences Inc PEPTIDE ANALOGUE OF THE HUMAN MYELINE-BASED PROTEIN WITH SUBSTITUTION IN POSITION 91 FOR TREATING MULTIPLE Sclerosis

Also Published As

Publication number Publication date
AU4278296A (en) 1996-05-15
FI971750A0 (en) 1997-04-24
NO971900D0 (en) 1997-04-24
WO1996012737A2 (en) 1996-05-02
IS4466A (en) 1997-04-17
PL324091A1 (en) 1998-05-11
JPH10504039A (en) 1998-04-14
SI9520118A (en) 1998-08-31
NO971900L (en) 1997-06-25
CA2203629A1 (en) 1996-05-02
CZ122697A3 (en) 1997-09-17
SK51297A3 (en) 1998-03-04
BR9509438A (en) 1997-12-23
HUT77047A (en) 1998-03-02
EP0787147A1 (en) 1997-08-06
IL115766A0 (en) 1996-01-19
WO1996012737A3 (en) 1996-10-10

Similar Documents

Publication Publication Date Title
FI971750A (en) Compositions and treatment for multiple sclerosis
FI971969A (en) Compositions for the treatment of hemorrhoids and method of use
FI970563A0 (en) Improved cleaning composition
FI955980A (en) Procedure and arrangement for reorganization
DE69513916T2 (en) Surface treatment composition
FI964330A (en) Procedure and apparatus for stairlifts
DE69521804D1 (en) CLEANING COMPOSITIONS
FI960483A (en) Changing composition and procedures for its use
FI962976A0 (en) Compositions for the treatment of galukoma containing pilocarpine and beta-blocker
DE69527272D1 (en) CLEANING COMPOSITION
FI972306A (en) Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-onei-1,1-diozide derivatives and these containing compositions and methods for their use
IL113661A0 (en) Compositions and treatment for multiple sclerosis
FI971138A0 (en) Ceramic insulators and processes for their manufacture
FI971376A0 (en) Trofinin and trofininmedlande proteiner
DE69527268D1 (en) CLEANING COMPOSITION
FI91347C (en) Procedure for performing time interval switching and time switching
FI972307A (en) 2- (2,3,5,6-tetrafluoro-4-pyridyl) 1,2,5-thiadiazolidin-3-onei-1,1-dioxides and these containing compositions and methods for their use
FI952030A0 (en) Smaeltprocessbar polyesteruretan och foerfarande Foer framstaellning daerav
SE9403758D0 (en) Arrangements for cleaning
SE9200329D0 (en) ALDIC AND CLEANING AGENTS
FIU940033U0 (en) Braennbart uppvaermningsredskap Foer Bruk utomhus och i eldstaeder
SE9400370L (en) Therapeutic composition for inhalation
ZA953730B (en) Compositions and treatment for multiple sclerosis
FI941614A0 (en) Foerfarande och anordning Foer saogning med bandsaog
FI941656A0 (en) Saekerhetsstoetfaongare och med saekerhetsskenor foersedd Kaross Foer en personbil